Ceftobiprole in cystic fibrosis: a case series
Ceftobiprole presents a therapeutic option for susceptible infections in CF patients with limited treatment options. Its broad-spectrum coverage may help to reduce polypharmacy. However, further clinical studies are needed.
Authors
- Silke Schelenz (ORCID: https://orcid.org/0000-0002-0108-4619)
- Newara Ramadan (ORCID: https://orcid.org/0000-0003-3628-559X)
- Lisa Nwankwo (ORCID: https://orcid.org/0000-0001-9146-2873)
Institutions
- King's College - North Carolina (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Harefield Hospital (GB)
- King's College Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf077
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00